Effect of Isotretinoin on Immune Activation Among HIV-1 Infected Subjects With Incomplete CD4+ T Cell Recovery
- Registration Number
- NCT01969058
- Lead Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Brief Summary
This phase II study was done in HIV-infected participants on antiretroviral therapy to evaluate the effects of isotretinoin (a drug that is approved for use in the treatment of severe acne) on the immune system. The immune system helps the body fight infections. When the immune system is not working well, one may be at greater risk for diseases that are common in aging, like heart disease, weaker bones, and kidney disease.
- Detailed Description
Isotretinoin was administered to participants in the Isotretinoin arm at approximately 0.5 mg/kg PO once daily for 4 weeks, then increased to approximately 1.0 mg/kg PO once daily for 12 weeks. Follow-up continues to week 28 to evaluate the duration of effect. Randomization was stratified by willingness to participate in the gut biopsy substudy, A5330s. The study population included HIV-1 infected adults whose virus was suppressed on ART, excluding women of child bearing potential.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 76
- HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by a licensed Western blot or a second antibody test by a method other than the initial rapid HIV and/or E/CIA, or by HIV-1 antigen, plasma HIV-1 RNA viral load.
NOTE: The term "licensed" refers to a US FDA-approved kit, which is required for all IND studies.
CDC (Centers for Disease Control and Prevention) guidelines mandate that confirmation of the initial test result must use a test that is different from the one used for the initial assessment. A reactive initial rapid test should be confirmed by either another type of rapid assay or an E/CIA that is based on a different antigen preparation and/or different test principle (eg, indirect versus competitive), or a Western blot or a plasma HIV-1 RNA viral load.
- Receiving ART therapy for at least 12 months prior to study entry.
- No plans to change the ART regimen in the 6 months after study entry.
- HIV-1 RNA below the lower limit of detection using an FDA-approved assay obtained within 30 days prior to study entry by any laboratory that has a CLIA certification or its equivalent (eg, <50 copies/mL on Roche Amplicor HIV-1 Monitor assay, <75 copies/mL on the Versant HIV-1 RNA assay by branched DNA, <40 copies/mL on the Abbott m2000sp/m2000rt real-time PCR test, < 20 copies/mL on the COBAS AmpliPrep/TAQMAN HIV-1 assay).
- All measurements of HIV-1 RNA within the 12 months prior to study entry must be below the limit of detection with the following exception:
NOTE A: 1 viral blip (<200 copies/mL) is permitted if it is preceded and followed by viral loads below the limits of detection.
NOTE B: The virologic assay must have a lower limit of detection of ≤ 75 copies/mL.
-
CD4+ cell count <350 cells/mm3 obtained at screening within 30 days prior to entry at any laboratory that has a CLIA (Clinical Laboratory Improvement Amendments) certification or its equivalent.
-
The following laboratory values obtained within 30 days prior to entry by any laboratory that has a CLIA certification or its equivalent:
- Hemoglobin A1c (HgbA1c) levels ≤ 6.5%
- Hemoglobin ≥ 9.0 g/dL
- Platelet count ≥ 50,000/mm3
- Creatinine ≤1.5 mg/dl
- CrCl ≥ 60 mL/min, calculated by the Cockcroft-Gault method
- Aspartate aminotransferase (AST) (SGOT) ≤1.5x upper limit of normal (ULN)
- Alanine aminotransferase (ALT) (SGPT) ≤1.5x ULN
- Serum lipase ≤1.5x ULN
- Fasting triglyceride level ≤200 mg/dL
- Fasting glucose <126mg/dL
-
Karnofsky performance score >/=70 within 30 days prior to entry.
-
Men and post-menopausal females aged ≥ 18 years and ≤ 80 years at entry.
Note: Post-menopausal is defined as having either:
- Appropriate medical documentation (see note) of prior complete bilateral oophorectomy (i.e., surgical removal of the ovaries, resulting in "surgical menopause" and occurring at the age at which the procedure was performed), OR
- Permanent cessation (12 consecutive months or more of amenorrhea) of previously occurring menses as a result of ovarian failure with documentation of hormonal deficiency by a certified healthcare provider (i.e., "spontaneous menopause").
Hormonal deficiency should be properly documented (see note) in the case of suspected spontaneous menopause as follows:
- If age >54 years and with the absence of normal menses: Serum FSH (Follicle Stimulating Hormone) level elevated to within the post-menopausal range based on the laboratory reference range where the hormonal assay is performed.
- If age ≤ 54 years and with the absence of normal menses: Negative serum or urine HCG with concurrently elevated serum FSH (follicle stimulating hormone) level in the post-menopausal range, depressed estradiol (E2) level in the post-menopausal range, and absent serum progesterone level, based on the laboratory reference ranges where the hormonal assays are performed.
NOTE: "Appropriate documentation", and "properly documented" means written documentation or oral communication from a clinician or clinician's staff documented in source documents of an operative report, discharge summary, or
- No active hepatitis B or C infection. NOTE: For subjects who have documentation of prior infection, but no active hepatitis infection, evidence of clearance must be greater than 1 year.
- Ability and willingness of subject to provide informed consent.
- Willingness to adhere to the iPLEDGE program requirements.
- Indication of willingness to participate in the substudy A5330s. NOTE: In the event that 12 or fewer subjects have enrolled into A5330s by the time enrollment in the main study has reached 50% of the accrual target, A5330s enrollment will be required.
- Pre-existing diagnosis of diabetes.
- Currently receiving treatment with fibrate, nicotinic acid, tetracycline, fish oil >1g/d, or methotrexate.
- Known active healing fracture or any severe bone disorders. NOTE: does not include healed fractures or history of old fractures.
- Receipt of any of the following medications within 30 days prior to entry: systemic steroids (including intra-articular steroids; inhaled or nasal steroid therapy is permitted), interleukins, systemic interferons (including intra-articular steroid injection; local injection of interferon alpha for treatment of human papilloma virus is permitted), or systemic chemotherapy.
- Known allergy/sensitivity or any hypersensitivity to vitamin A, retinoids, or any of their derivatives.
- Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
- Acute or serious illness requiring systemic treatment and/or hospitalization within 60 days prior to entry.
- Weight < 40 kg or > 150 kg.
- History of major depression or suicide attempt requiring hospitalization, or psychotic episode requiring medication or hospitalization.
- History of inflammatory bowel disease such as Crohn's disease, or Ulcerative colitis.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Isotretinoin Arm Isotretinoin Participants received Isotretinoin at approximately 0.5 mg/kg orally once daily for 4 weeks, then increased to approximately 1.0 mg/kg orally once daily for 12 weeks.
- Primary Outcome Measures
Name Time Method Change in CD8+ T-cell Activation From Baseline to Week 14/16 baseline, week 14/16 Level of CD8+ T-cell activation was determined by measuring the percentage of CD8+ T-cells that expressed both the activation marker CD38+ and Human leukocyte antigen (HLA)-DR+. The endpoint is measuring the change from baseline to week 14/16, where baseline is defined as the average of pre-entry and entry, and week 14/16 is defined as the average of week 14 and week 16.
Change = (week 14/16 - baseline).
- Secondary Outcome Measures
Name Time Method Change in sTNF-r2 baseline, week 14/16, week 28 sTNF-r2 (soluble tumour necrosis alpha receptor 2) is a marker of inflammation. Change in log10 transformed sTNF-r2 from baseline to week 14/16 (week 14/16 - baseline), from week 14/16 to week 28 (week 28 - week 14/16), and from baseline to week 28 (week 28 - baseline).
Levels measured at pre-entry and entry were averaged for baseline, levels measured at week 14 and week 16 were averaged for week 14/16.Change in sCD163 baseline, week 14/16, week 28 sCD163 (soluble CD 163) is a marker of macrophage activation Change in log10 transformed sCD163 from baseline to week 14/16 (week 14/16 - baseline), from week 14/16 to week 28 (week 28 - week 14/16), and from baseline to week 28 (week 28 - baseline).
Levels measured at pre-entry and entry were averaged for baseline, levels measured at week 14 and week 16 were averaged for week 14/16.Change in sTNF-r1 baseline, week 14/16, week 28 sTNF-r1 (soluble tumour necrosis alpha receptor 1) is a marker of inflammation. Change in log10 transformed sTNF-r1 from baseline to week 14/16 (week 14/16 - baseline), from week 14/16 to week 28 (week 28 - week 14/16), and from baseline to week 28 (week 28 - baseline).
Levels measured at pre-entry and entry were averaged for baseline, levels measured at week 14 and week 16 were averaged for week 14/16.Change in CD4+ T-cell Count baseline, week 14/16, week 28 Change in peripheral total CD4 cell count from baseline to week 14/16 (week 14/16 - baseline), from week 14/16 to week 28 (week 28 - week 14/16), and from baseline to week 28 (week 28 - baseline).
Levels measured at pre-entry and entry were averaged for baseline, levels measured at week 14 and week 16 were averaged for week 14/16.Cell-associated HIV-1 DNA baseline, week 14/16, week 28 Cell-associated HIV-1 DNA in blood at baseline, week 14/16, and week 28. Levels measured at pre-entry and entry were averaged for baseline, levels measured at week 14 and week 16 were averaged for week 14/16.
For cell-associated HIV-1 DNA results below the assay limit, the lowest value of the sample was imputed to these results and considered lowest ranks (1.62 log10 copies/10\^6 CD4 cells).
It was originally planned to summarize the absolute changes for cell-associated HIV-1 DNA. However, since there are many results below limit of detection, analyzing the absolute changes would be inappropriate in this case.
Instead, the baseline, week 14/16, and week 28 levels were summarized.Change in IL-6 baseline, week 14/16, week 28 IL-6 (Interleukin-6) is a marker of systemic inflammation. The outcome measures are changes in log10 transformed IL-6 from baseline to week 14/16 (week 14/16 - baseline), from week 14/16 to week 28 (week 28 - week 14/16), and from baseline to week 28 (week 28 - baseline).
Levels measured at pre-entry and entry were averaged for baseline, levels measured at week 14 and week 16 were averaged for week 14/16.Change in hsCRP baseline, week 14/16, week 28 hsCRP (high-sensitivity C-reactive protein) is a marker of inflammation. Change in log10 transformed hsCRP from baseline to week 14/16 (week 14/16 - baseline), from week 14/16 to week 28 (week 28 - week 14/16), and from baseline to week 28 (week 28 - baseline).
Levels measured at pre-entry and entry were averaged for baseline, levels measured at week 14 and week 16 were averaged for week 14/16.Change in D-dimer baseline, week 14/16, week 28 D-dimer (or D dimer) is a marker of coagulation activation. Change in log10 transformed D-dimer from baseline to week 14/16 (week 14/16 - baseline), from week 14/16 to week 28 (week 28 - week 14/16), and from baseline to week 28 (week 28 - baseline).
Levels measured at pre-entry and entry were averaged for baseline, levels measured at week 14 and week 16 were averaged for week 14/16.Change in TF baseline, week 14/16, week 28 TF (Tissue Factor) is a marker of Coagulation. Change in log10 transformed TF from baseline to week 14/16 (week 14/16 - baseline), from week 14/16 to week 28 (week 28 - week 14/16), and from baseline to week 28 (week 28 - baseline).
Levels measured at pre-entry and entry were averaged for baseline, levels measured at week 14 and week 16 were averaged for week 14/16.Change in Cell-associated HIV-1 RNA baseline, week 14/16, week 28 Cell-associated HIV-1 RNA in blood from baseline to week 14/16(week 14/16 - baseline), from week 14/16 to week 28 (week 28 - week 14/16), and from baseline to week 28 (week 28 - baseline).
Levels measured at pre-entry and entry were averaged for baseline, levels measured at week 14 and week 16 were averaged for week 14/16.
For cell-associated HIV-1 RNA results below the assay limit, the lowest value of the sample was imputed to these results (1.32 log10 copies/10\^6 CD4 cells).
Since there are only a few results below the assay limit, it is still reasonable to summarize the absolute changes for cell-associated HIV-1 RNA, where changes were calculated based on the imputed values (described above) for below assay limit results.Change in Treg Frequency (%FoxP3+/CD25hi+/CD39+/CD127-(CD4+)) baseline, week 14/16, week 28 Treg (T Regulatory) Cells are a subpopulation of T cells which modulate the immune system.
The outcome measure is the change in percent FoxP3+/CD25hi+/CD39+/CD127-(CD4+) from baseline to week 14/16 (week 14/16 - baseline), from week 14/16 to week 28 (week 28 - week 14/16), and from baseline to week 28 (week 28 - baseline).
Levels measured at pre-entry and entry were averaged for baseline, levels measured at week 14 and week 16 were averaged for week 14/16.Change in Th17 Frequency (%IFNg-/IL17+(CD161+/CCR6+)) baseline, week 14/16, week 28 Th17 (T-helper 17) cells are a subset of pro-inflammatory T helper cells defined by their production of interleukin 17 (IL-17).
The outcome is the change in percent IFNg-/IL17+(CD161+/CCR6+) from baseline to week 14/16 (week 14/16 - baseline), from week 14/16 to week 28 (week 28 - week 14/16), and from baseline to week 28 (week 28 - baseline).
Levels measured at pre-entry and entry were averaged for baseline, levels measured at week 14 and week 16 were averaged for week 14/16.Change in CD8+ T-cell Activation baseline, week 14/16, week 28 Level of CD8+ T-cell activation was determined by measuring the percentage of CD8+ T-cells that expressed both the activation marker CD38+ and Human leukocyte antigen (HLA)-DR+.
The endpoint is measuring the change from week 14/16 to week 28 (week 28 - week 14/16) and from baseline to week 28 (week 28 - baseline).
Baseline is defined as the average of pre-entry and entry, and week 14/16 is defined as the average of week 14 and week 16.Change in sCD14 baseline, week 14/16, week 28 sCD14 (soluble cluster of differentiation 14) is a marker of gut microbial translocation and monocyte activation.
The outcome measures are changes in log10 transformed sCD14 from baseline to week 14/16 (week 14/16 - baseline), from week 14/16 to week 28 (week 28 - week 14/16), and from baseline to week 28 (week 28 - baseline).
Levels measured at pre-entry and entry were averaged for baseline, levels measured at week 14 and week 16 were averaged for week 14/16.Change in I-FABP baseline, week 14/16, week 28 I-FABP (intestinal-fatty acid binding protein) is a marker of intestinal cell damage and turnover.
The outcome measures are changes in log10 transformed I-FABP from baseline to week 14/16 (week 14/16 - baseline), from week 14/16 to week 28 (week 28 - week 14/16), and from baseline to week 28 (week 28 - baseline).
Levels measured at pre-entry and entry were averaged for baseline, levels measured at week 14 and week 16 were averaged for week 14/16.Pharmacokinetics - 12-hour Levels of EFV for Isotretinoin Arm weeks 0, 8, 12, 16, 20 Isotretinoin arm (Arm A) only, 12-hour levels of EFV (Efavirenz) is defined as the average of 'eligible' concentrations, where 'eligible' means the time from the previous dose to the blood draw of the sample must have been in the 9-to-15 hour range, and the participant must have taken at least 3 doses in the prior 4 days.
EFV trough during Isotretinoin administration is the average of 'eligible' concentrations from weeks 8, 12, and 16; EFV trough without Isotretinoin administration is the average of 'eligible' concentrations from weeks 0 and 20.
(Week 28 data is not available.)Pharmacokinetics - Trough Concentrations of TDF for Isotretinoin Arm weeks 0, 8, 12, 16, 20 Isotretinoin arm (Arm A) only, trough concentrations of TDF (Tenofovir) is defined as the average of 'eligible' concentrations, where 'eligible' means the time from the previous dose to the blood draw of the sample must have been in the 20-to-28 hour range, and the participant must have taken at least 3 doses in the prior 4 days.
TDF trough during Isotretinoin administration is the average of 'eligible' concentrations from weeks 8, 12, and 16; TDF trough without Isotretinoin administration is the average of 'eligible' concentrations from weeks 0 and 20.
(Week 28 data is not available.)Pharmacokinetics - Endogenous Levels of Retinoid Metabolites for Isotretinoin Arm weeks 0, 20, 28 Isotretinoin Arm (Arm A) only. Endogenous retinoid metabolites are defined as the average concentrations of Retinol, and Total Retinyl Ester from weeks 0, 20, and 28.
Pharmacokinetics - Steady-state Trough Concentrations of Isotretinoin for Isotretinoin Arm weeks 8, 12, 16 Isotretinoin arm (Arm A) only, steady-state trough concentrations of Isotretinoin is defined as the average of 'eligible' concentrations at weeks 8, 12, and 16, where 'eligible' means the time from the previous dose to the blood draw of the sample must have been in the 14-to-30 hour range, and the participant must have taken at least 3 doses in the prior 4 days.
Primary Targeted Adverse Events from study entry to end of study (week 28) Targeted events for A5325 include: events that meet the International Conference on Harmonization (ICH) definitions for a serious adverse event, post-entry signs/symptoms and laboratory abnormalities of Grade ≥3 or that lead to a change in treatment regardless of grade, and any diagnoses.
Trial Locations
- Locations (15)
601 University of California, Los Angeles CARE Center CRS
🇺🇸Los Angeles, California, United States
107 Brigham and Women's Hosp. ACTG CRS
🇺🇸Boston, Massachusetts, United States
3203 Greensboro CRS
🇺🇸Greensboro, North Carolina, United States
31788 Alabama CRS
🇺🇸Birmingham, Alabama, United States
3201 Chapel Hill CRS
🇺🇸Chapel Hill, North Carolina, United States
2101 Washington University Therapeutics (WT) CRS
🇺🇸Saint Louis, Missouri, United States
101 Massachusetts General Hospital (MGH) CRS
🇺🇸Boston, Massachusetts, United States
2951 The Miriam Hospital (TMH) ACTG CRS
🇺🇸Providence, Rhode Island, United States
5401 Puerto Rico AIDS Clinical Trials Unit CRS
🇵🇷San Juan, Puerto Rico
2401 Cincinnati CRS
🇺🇸Cincinnati, Ohio, United States
801 University of California, San Francisco HIV/AIDS CRS
🇺🇸San Francisco, California, United States
3652 Vanderbilt Therapeutics (VT) CRS
🇺🇸Nashville, Tennessee, United States
31473 Houston AIDS Research Team (HART) CRS
🇺🇸Houston, Texas, United States
31786 New Jersey Medical School Clinical Research Center CRS
🇺🇸Newark, New Jersey, United States
31787 University of Rochester Adult HIV Therapeutic Strategies Network CRS
🇺🇸Rochester, New York, United States